20:50 , Jun 28, 2018 |  BC Innovations  |  Translation in Brief

Against the gradient

In a paper published in...
08:00 , Feb 9, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Solute carrier family 12 potassium-chloride transporter member 2 (SLC12A2, NKCC1); p75 neurotrophin receptor (p75 NTR) Studies in mice suggest that bumetanide could help treat...
08:00 , Jan 23, 2012 |  BC Week In Review  |  Company News

Only for Children, Swedish Orphan Biovitrum deal

Only for Children granted Swedish Orphan Biovitrum rights to commercialize bumetanide reformulated to treat diuresis and seizures in neonates. Only for Children is responsible for obtaining market authorizations. Only for Children will receive €300,000 ($380,310)...
08:00 , Nov 24, 1997 |  BC Week In Review  |  Clinical News

Gensia regulatory update

GNSA's Gensia Laboratories Ltd. subsidiary (Irvine, Calif.) received ANDA approval from the FDA for bumetanide injection for the acute treatment of edema associated with congestive heart failure and hepatic and renal disease in patients with...